{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:34Z","timestamp":1783075894780,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["brainanddevelopment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.braindev.2014.11.008","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T04:46:09Z","timestamp":1420692369000},"page":"773-779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The efficacy of levetiracetam for focal seizures and its blood levels in children"],"prefix":"10.1016","volume":"37","author":[{"given":"Toshiyuki","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taira","family":"Toki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Nonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.braindev.2014.11.008_b0005","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1046\/j.1528-1157.2001.00003.x","article-title":"Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?","volume":"42","author":"Klitgaard","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.braindev.2014.11.008_b0010","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.braindev.2014.11.008_b0015","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007691-200312000-00007","article-title":"Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication","volume":"25","author":"May","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.braindev.2014.11.008_b0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1345\/aph.1A032","article-title":"Levetiracetam: a different approach to the pharmacotherapy of epilepsy","volume":"36","author":"Welty","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.braindev.2014.11.008_b0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.seizure.2009.05.007","article-title":"Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy","volume":"18","author":"Giroux","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.braindev.2014.11.008_b0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1472-8206.2001.00055.x","article-title":"Clinical pharmacology and therapeutic use of the new antiepileptic drugs","volume":"15","author":"Perucca","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.braindev.2014.11.008_b0035","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00415-004-0344-0","article-title":"Drug selection for the newly diagnosed patient: when is a new generation antiepileptic drug indicated?","volume":"251","author":"Tomson","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2014.11.008_b0040","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.braindev.2014.11.008_b0045","first-page":"409","article-title":"Levetiracetam in the treatment of childhood epilepsy","volume":"3","author":"Wheless","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.braindev.2014.11.008_b0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11316250-000000000-00000","article-title":"Levetiracetam in childhood epilepsy","volume":"12","author":"Verrotti","year":"2010","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.braindev.2014.11.008_b0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.braindev.2014.11.008_b0060","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1046\/j.1528-1157.2001.41300.x","article-title":"Pharmacokinetic study of levetiracetam in children","volume":"42","author":"Pellock","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.braindev.2014.11.008_b0065","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejpn.2007.02.016","article-title":"Long-term use of levetiracetam in patients with severe childhood-onset epilepsy","volume":"11","author":"von Stuelpnagel","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2014.11.008_b0070","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.braindev.2012.07.005","article-title":"Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy","volume":"35","author":"Kanemura","year":"2013","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2014.11.008_b0075","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.0013-9580.2005.31504.x","article-title":"Rapid onset of action of levetiracetam in refractory epilepsy patients","volume":"46","author":"French","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.braindev.2014.11.008_b0080","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/FTD.0b013e318157032d","volume":"29","author":"Lancelin","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.braindev.2014.11.008_b0085","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1528-1167.2007.01090.x","article-title":"Pharmacokinetics of levetiracetam in infants and young children with epilepsy","volume":"48","author":"Glauser","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.braindev.2014.11.008_b0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2006.12.005","article-title":"Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate","volume":"74","author":"Fountain","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.braindev.2014.11.008_b0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00323-0","article-title":"Dose-response effect of levetiracetam 1000 and 2000mg\/day in partial epilepsy","volume":"48","author":"Boon","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.braindev.2014.11.008_b0100","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1468-1331.2006.01381.x","article-title":"Assessment of a dose-response relationship of levetiracetam","volume":"13","author":"Meencke","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.braindev.2014.11.008_b0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.braindev.2013.04.006","article-title":"The efficacy of gabapentin in children of partial seizures and the blood levels","volume":"36","author":"Nonoda","year":"2014","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2014.11.008_b0110","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2014.11.008_b0115","unstructured":"Food and Drug Administration [Internet]. Silver Spring: NDA 21035\/S-089 & NDA 21505\/S-030 Keppra tablet and oral solution FDA Approved Labeling text dated Jul 2013. Available from: <http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/>."},{"key":"10.1016\/j.braindev.2014.11.008_b0120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-2999(92)90855-X","article-title":"Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals","volume":"222","author":"Gower","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.braindev.2014.11.008_b0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2014.11.008_b0130","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000 mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760414002848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760414002848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T12:29:52Z","timestamp":1537964992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760414002848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0387760414002848"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2014.11.008","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of levetiracetam for focal seizures and its blood levels in children","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2014.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}